Key Points
- Use the highest‑yield diagnostic test early; do not let testing delay time‑critical therapy.
- Set objective targets and reassess frequently.
- Plan definitive source control or disease‑specific therapy when indicated; document follow‑up and patient education.
Algorithm
- Resuscitate; start octreotide and ceftriaxone; correct coagulopathy pragmatically.
- Early EGD with band ligation; if uncontrolled → balloon tamponade as bridge.
- Consider early TIPS for high‑risk (Child‑Pugh C) or rebleed; start non‑selective β‑blocker for secondary prophylaxis.
Clinical Synopsis & Reasoning
In cirrhosis with hematemesis/melena, start vasoactive therapy (octreotide) and prophylactic antibiotics immediately, resuscitate with restrictive transfusion, and perform early endoscopy for band ligation. Use balloon tamponade as a bridge if uncontrollable hemorrhage and consider early TIPS for high‑risk or refractory bleeding.
Treatment Strategy & Disposition
Stabilize ABCs. Initiate guideline‑concordant first‑line therapy with precise dosing and continuous monitoring. Escalate to advanced/procedural interventions based on explicit failure criteria. Define ICU, step‑down, and ward disposition triggers; involve specialty teams early.
Epidemiology / Risk Factors
- Risk varies by comorbidity and precipitants; see citations for condition‑specific data.
Investigations
| Test | Role / Rationale | Typical Findings | Notes |
|---|
| CBC, INR, fibrinogen; type & cross | Resuscitation | Guide transfusion | Restrictive strategy (Hb ~7) |
| EGD within 12 hours | Diagnosis/therapy | Variceal source; banding | — |
| Ultrasound/Doppler (portal vein) | Etiology | Portal hypertension/thrombosis | TIPS planning |
High-Risk & Disposition Triggers
| Trigger | Why it matters | Action |
|---|
| Instability or organ dysfunction | High risk | ICU; escalate care |
| Failure of first-line therapy | Refractory | Advance pathway; consult subspecialists |
| Severe comorbidity/pregnancy/immunosuppression | Higher risk | Lower threshold to admit |
| Poor follow-up access | Safety | Prefer observation/admission |
| Diagnostic uncertainty with red flags | Missed diagnosis risk | Serial exams and monitoring |
Pharmacology
| Medication/Intervention | Mechanism | Onset | Role in Therapy | Limitations |
|---|
| Octreotide 50 µg IV bolus → 50 µg/h infusion (or Terlipressin) | Vasoactive | Minutes | Reduce portal inflow | Continue 2–5 days |
| Ceftriaxone 1 g IV daily ×7 days | Antibiotic prophylaxis | Hours | Reduce infections/rebleed/mortality | — |
| Endoscopic band ligation (EVL) ± Balloon tamponade as bridge | Endoscopic/bridge | Hours | Definitive control/temporary control | Consider early TIPS in high‑risk |
Prognosis / Complications
- Outcome depends on timeliness of diagnosis and definitive therapy; monitor for complications.
Patient Education / Counseling
- Provide red‑flag education, adherence guidance, and explicit return precautions; arrange timely specialty follow‑up.
References
- Baveno/Texas consensus on portal hypertension and variceal bleeding — Link